Echinocandin Resistance Increasing in Candida glabrata

Unlike fluconazole-resistant bloodstream isolates from 2001–2004, those from 2006–2010 showed reduced susceptibility and resistance to echinocandins.

Broadening resistance to azoles has driven the use of echinocandins to treat invasive candidiasis caused by Candida glabrata. Preliminary reports of echinocandin resistance among azole-resistant C. glabrata isolates prompted researchers to test bloodstream isolates obtained from two large antifungal surveys: the SENTRY Global Surveillance Program (847 isolates from diverse medical centers worldwide in 2006–2010) and the CDC population-based surveillance program (822 isolates from metropolitan Atlanta and Baltimore in 2008–2010). Results were compared with those for 110 fluconazole-resistant isolates collected from medical centers worldwide in 2001 to 2004.

The isolates collected in 2001 to 2004 were all susceptible to echinocandins. Of the 1…

Reviewing Author

Larry M. Baddour, MD

Disclosures

RoyaltiesUpToDate, Inc. (Authorship duties)

Larry M. Baddour, MD

Disclosures

RoyaltiesUpToDate, Inc. (Authorship duties)